Duke University Medical Center, Box 102359 DUMC, Durham NC 27710, USA.
Infect Dis Clin North Am. 2021 Jun;35(2):341-371. doi: 10.1016/j.idc.2021.03.005.
Over the past 15 years, there has been an increase in the development and utilization of newer antifungal agents. The ideal antifungal, however, in regard to spectrum of activity, pharmacokinetic/pharmacodynamic properties, development of resistance, safety, and drug interaction profile remains elusive. This article reviews pharmacologic aspects of Food and Drug Administration-approved polyenes, flucytosine, azoles, and echinocandins as well as promising pipeline antifungal agents. Unique properties of these newer agents are highlighted. The clinical role of established and investigational antifungal agents as treatment and/or prevention of invasive fungal infections is discussed.
在过去的 15 年中，新型抗真菌药物的开发和利用有所增加。然而，就作用谱、药代动力学/药效学特性、耐药性的发展、安全性和药物相互作用谱而言，理想的抗真菌药物仍难以捉摸。本文回顾了美国食品和药物管理局批准的多烯类、氟胞嘧啶、唑类和棘白菌素类药物以及有前途的抗真菌药物的药理学方面。强调了这些新型药物的独特特性。讨论了已确立和研究中的抗真菌药物在治疗和/或预防侵袭性真菌感染中的临床作用。
